$Coherus BioSciences (CHRS.US)$im watching closely for this ( Coherus anticipates demand will continue to rise with significantly improved commercial and Medicare Advantage formulary coverage in the fourth quarter of 2023 and in 2024.)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Khayfoong : why this terrible drop?
Trytosaveabit OP Khayfoong : Earnings was bad! They cut their guidance for next year and analysts cut the PT almost by half! GL![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Khayfoong :![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
gg